Pharmaceuticals News and Research

RSS

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Every year, billions of dollars worth of vaccines are shipped to thousands of medical providers across the country, and every year doctors must dispose of tens of millions of dollars worth of those vaccines because they became too warm or too cold while in storage.

27 Jan 2010

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).

27 Jan 2010

Labcyte introduces pre-calibrated liquid class packages for use with its Echo acoustic dispensers

Today Labcyte introduced two pre-calibrated liquid class packages for use with its award-winning Echo® acoustic dispensers and POD™ 810 plate assemblers, which move liquids with sound. This expanded capability will allow its high throughput screening customers to not only transfer compounds in DMSO, but enables the transfer of a wide range of liquids necessary to assemble miniaturized assays for biochemical and cell-based screening.

27 Jan 2010

Regular exercise associated with greater longevity and reduced risk of age-related conditions

Physical activity appears to be associated with a reduced risk or slower progression of several age-related conditions as well as improvements in overall health in older age, according to a commentary and four articles published in the January 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jan 2010

Health News Digest features Sunridge International's patented 'PNT' procedure

Sunridge International's patented "PNT" procedure was the topic of discussion in one of Health News Digest's recent articles published on January 24, 2010.

27 Jan 2010

New disease management initiative in Colorado aims to treat low back pain and improve patient outcomes

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that by increasing the role of the primary-care physician, the recently launched Colorado Low Back Collaborative (CLBC) aims to treat lower back issues with a more holistic view, and ultimately improve patient outcomes while lowering costs associated with the care of low back pain.

27 Jan 2010

Cees Veerman committee recommends continuation of TI Pharma in its present form

Top Institute Pharma (TI Pharma) enables unique public-private collaborations that are extremely valuable for pharmaceutical research in the Netherlands. This can be read in the Midterm Review (MTR) of the Top Institute, which was published today. In the report, an independent committee chaired by Cees Veerman concludes that TI Pharma is well on its way to achieving the objectives that were determined at the time of its establishment. The institute addresses issues with marked social relevance, attracts international investments and has brought forth a group of quality researchers.

27 Jan 2010

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

27 Jan 2010

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

27 Jan 2010

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).

27 Jan 2010

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a fibromyalgia drug that improves sleep quality more than Pfizer's Lyrica would earn a 38 percent patient share in the U.S. and a 30 percent patient share in Europe due to its efficacy, safety and tolerability, and delivery.

27 Jan 2010

U.S. court decision favors Teva in generic Temodar ANDA litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough’s brain tumor treatment Temodar® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.

27 Jan 2010

Radient Pharmaceuticals' business plan submitted to NYSE Amex

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) announced today it has submitted a business plan to the New York Stock Exchange ("NYSE") Amex demonstrating its ability to achieve compliance with continued listing standards.

27 Jan 2010

State news: New York Governor wants regulation on Rx gifts to doctors and other state news

The Associated Press/CNBC reports that New York Gov. David Paterson is "proposing new, tougher prohibitions on pharmaceutical companies, restricting them from dispensing gifts and misleading production information to doctors while promoting the use of specific drugs."

27 Jan 2010

UF researchers work out to find new treatments for Pompe disease

As scientists work to find new treatments for Pompe disease - the devastating genetic "villain" that drives the efforts of the main characters in the new film "Extraordinary Measures" - University of Florida researchers are hopeful that gene therapy will help patients in the late stages of the disease breathe on their own.

27 Jan 2010

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.

27 Jan 2010

Intercept Pharmaceuticals completes $25M Preferred Series B financing

Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.

27 Jan 2010

Sumavel DosePro and Levadex to earn up to $400M by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Zogenix/Astellas Pharma/Desitin Pharmaceuticals' needle-free Sumavel DosePro, which launched earlier this month in the United States, and MAP Pharmaceuticals' orally-inhaled Levadex will earn approximately $400 million in combined sales by 2018 in the migraine drug market.

27 Jan 2010

Pharmaceuticals News and Research

NIST researchers determine best practices for storing and monitoring refrigerated vaccines

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Labcyte introduces pre-calibrated liquid class packages for use with its Echo acoustic dispensers

Regular exercise associated with greater longevity and reduced risk of age-related conditions

Health News Digest features Sunridge International's patented 'PNT' procedure

New disease management initiative in Colorado aims to treat low back pain and improve patient outcomes

Cees Veerman committee recommends continuation of TI Pharma in its present form

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Jubilant Biosys, Endo Pharmaceuticals expand their drug discovery partnership in oncology

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Fibromyalgia drug to earn 38% patient share in the U.S. and 30% patient share in Europe

U.S. court decision favors Teva in generic Temodar ANDA litigation

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Eribis Pharmaceuticals' cardiovascular therapy program receives new investment from Karolinska Development

Radient Pharmaceuticals' business plan submitted to NYSE Amex

State news: New York Governor wants regulation on Rx gifts to doctors and other state news

UF researchers work out to find new treatments for Pompe disease

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

Intercept Pharmaceuticals completes $25M Preferred Series B financing

Sumavel DosePro and Levadex to earn up to $400M by 2018

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence